title: Inhibition by aspirin of the stimulated PGI2 synthesis after administration of kallikrein to hypertensive patients (new aspects of chemical pathogeny concerning the messenger systems: A and C).
abstract: The vascular smooth muscle cells belong to the category of "bidirectionally controlled cells", which can be activated (leading to contraction) by some first-messengers (such as Catecholamine-alpha 1, or Angiotensin II) in connection with a recently discovered intracellular second-messenger system-C (sms-C), namely, Diacylglycerol-dependent Protein Kinase-C + Calcium mobilization. On the other hand, these cells can be inhibited (leading to relaxation) by other first-messengers (such as Catecholamine-beta or PGI2) related to the classical "second-messenger system-A" (sms-A), namely: Ns--Adenylate Cyclase--cAMP--Protein Kinase-A. It is also known that kallikrein (via kinins) can stimulate PGI2 synthesis, and implicitly sms-A, relaxing the vascular tone by counteracting the opposite pressor effect of sms-C. In the four h samples of urine, collected before and after administration of kallikrein (i.m., 40 IU) to six hypertensive patients, we measured (RIA): 6-keto-PGF1 alpha, the stable metabolite of PGI2. The results 5.86 +/- 1.25 vs 9.94 +/- 0.6 pg/mL +/- SEM (p less than 0.05) indicate a rise in PGI2 synthesis. However, no such effect was obtained when the same patients were given aspirin (4 g in divided doses) one day before repeating the above test: 5.59 +/- 1.97 vs 6.85 +/- 1.28 (NS). We may conclude that administration of kallikrein can stimulate PGI2 synthesis, which, in turn, can be blocked by relatively high (= nocive) doses of aspirin. Some new aspects of chemical physiology, pathogeny and systematization of the two major messenger systems, MS-A and MS-C, are discussed.
authors.forename: D D
authors.initials: DD
authors.lastname: Belloiu
authors.forename: A
authors.initials: A
authors.lastname: Briese
authors.forename: A
authors.initials: A
authors.lastname: Tarnovschi
authors.forename: I
authors.initials: I
authors.lastname: Belloiu
authors.forename: R
authors.initials: R
authors.lastname: Tabata
authors.forename: K
authors.initials: K
authors.lastname: Stergiopoulos
mesh_terms: D015121:6-Ketoprostaglandin F1 alpha / Q000652:urine; D001241:Aspirin / Q000494:pharmacology*; D001794:Blood Pressure / Q000187:drug effects; D000242:Cyclic AMP / Q000378:metabolism; D011464:Epoprostenol / Q000037:antagonists & inhibitors / Q000096:biosynthesis* / Q000652:urine; D006801:Humans; D006973:Hypertension / Q000378:metabolism*; D007273:Injections, Intramuscular; D007610:Kallikreins / Q000008:administration & dosage*; D009131:Muscle, Smooth, Vascular / Q000166:cytology
chemical_list: D015121:6-Ketoprostaglandin F1 alpha; D011464:Epoprostenol; D000242:Cyclic AMP; D007610:Kallikreins; D001241:Aspirin